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Physiologically based pharmacokinetic models are being used in an increasing number
of different areas. However, they are perceived as complex, data hungry, resource inten-
sive, and time consuming. In addition, model validation and veriﬁcation are hindered by
the relative complexity of the equations. To begin to address these issues a web applica-
tion called MEGen for the rapid construction and documentation of bespoke deterministic
PBPK model code is under development. MEGen comprises a parameter database and a
model code generator that produces code for use in several commercial software packages
and one that is freely available. Here we present an overview of the current capabilities of
MEGen, and discuss future developments.
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INTRODUCTION
Pharmacokinetics (PK) has a vital role in the safety assessment
and efﬁcacy of pharmaceuticals (ICH, 1995; Baldrick, 2003).
Recent activity to improve the risk assessment (RA) of non-
pharmaceuticals, such as pesticides and biocides, has led to the
revision of Directive 91/414/EC for pesticide use in the EU to
include a requirement for the generation and use of PK informa-
tion. Similarly, the REACH legislation acknowledges the potential
for PK data to inﬂuence the development of testing strategies
and optimization of study design for industrial chemicals and
chemicals used in consumer goods, including food. However, the
human chemical RA arena may be described as “data poor” as
opposed to the “data rich” pharmaceutical arena. The lack of
controlled human exposure data on most toxic chemicals makes
necessary the inference of human susceptibility, most commonly
from studies conducted in animals, human biological monitor-
ing data (if available), and alternatives to animal measures of
toxicity (in the future). This requires a speciﬁc type of PK. The
most effective inter-species and in vitro – in vivo extrapolation
is achieved using physiologically based pharmacokinetic (PBPK)
modeling because model structure for one species differs from
another only in terms of organ and tissue mass and blood ﬂow
rates and species-speciﬁc active processes (Clewell and Andersen,
1985; Krishnan and Andersen, 1994; Shiran et al., 2006; Rostami-
Hodjegan and Tucker, 2007; Jamei et al., 2009). PBPK modeling is
a powerful means of simulating the factors that determine tissue
dose within any biological organism and consequently, correlation
with health effects. The value of PBPKmodels is that they are tools
for integrating in vitro and in vivo mechanistic, pharmacokinetic,
and toxicological information (DeJongh et al., 1999; Forsby and
Blaauboer, 2007). This is achieved through their explicit math-
ematical description of important anatomical, physiological and
biochemical determinants of chemical uptake, disposition, and
elimination. Thus, PBPK modeling is increasingly being used in
chemical RA.
The increasing use of tissue dosimetry estimated using PBPK
models has led to initiatives to develop internationally recognized
good modeling practices (Clark et al., 2004; Barton et al., 2007;
Chiu et al., 2007; Loizou et al., 2008; Thompson et al., 2008;WHO,
2010). It is envisaged that goodmodeling practices would facilitate
the sharing of models and model evaluations and lead to consis-
tent applications in RA. Good modeling practices would include
guidance on model development, characterization, documenta-
tion, and evaluation (Loizou et al., 2008). However, PBPK models
are perceived as complex, data hungry, resource intensive, and
time consuming. In addition, model validation and veriﬁcation
are hindered by the relative complexity of the equations. To begin
to address these issues a web application for the rapid construc-
tion and documentation of bespoke PBPK model code is under
development. Here we present an overview of the current capabil-
ities of MEGen, a model equation generator (EG) and parameter
database, and we discuss future developments.
MATERIALS AND METHODS
Web application: MEGen Version 0.51
SIMULATION SOFTWARE
AcslXLiberoVersion3.0.1.6 (TheAegisTechnologiesGroup Inc.2),
BerkeleyMadonnaVersion 8.3.183,MATLABversionR2010b (The
Mathworks, Natick, MA, USA4).
1http://xnet.hsl.gov.uk/megen
2www.acslsim.com
3www.berkeleymadonna.com
4www.mathworks.com
www.frontiersin.org November 2011 | Volume 2 | Article 56 | 1
Loizou and Hogg MEGen: a physiologically based pharmacokinetic model generator
DIGITIZING SOFTWARE
Grab It! Graph Digitizer (Datatrend Software, Inc.5).
The computer used in this study was a Dell Optiplex 755 Intel
Core (TM)2 Duo CPU 3.00GHz 2.00GB RAM.
MODEL DEVELOPMENT
Three PBPK models from the peer-reviewed literature were cho-
sen to demonstrate a selection of current capabilities of MEGen.
These are the generation of PBPK models for
• Simulation of closed-chamber exposure.
• Simulation of glutathione depletion by conjugation with
metabolites of oxidative metabolism.
• Simulation of intra-venous administration and metabolism by
multiple enzyme isoforms.
CLOSED-CHAMBER EXPOSURE
The model of Himmelstein et al. (2004) for the simulation of
closed-chamber exposure of the B6C3F1 mouse to β-chloroprene
using equipment of the type described by Gargas et al. (1986) and
Loizou et al. (1996).
GLUTATHIONE DEPLETION
The model of Clewell et al. (2001) describing high and low afﬁn-
ity oxidation of vinyl chloride to reactive metabolites that are
conjugated with glutathione causing depletion of the latter.
INTRA-VENOUS EXPOSURE AND ENZYME POLYMORPHISMS
The human PBPK model describing intra-venous infusion and
hepatic ethanol metabolism by cytochrome P450 and three iso-
forms of alcohol dehydrogenase (Pastino et al., 2000)wasmodiﬁed
to simulate oral and intra-venous administration (Loizou and
Spendiff, 2004).
Anatomical, physiological, biochemical, and physicochemical
parameters used by the various authors required to construct the
PBPK models were obtained from their respective publications
and stored in the database. The models were built using MEGen
as described below. The experimental data points in Figures 5–7
of this report were obtained by digitizing Figure 2A of Himmel-
stein et al. (2004), Figure 5 of Clewell et al. (2001) and Figure 5 of
Loizou and Spendiff (2004).
The models were exported in three widely used software
syntaxes, Berkeley Madonna, acslX, and MATLAB.
PROGRAM DESCRIPTION
OVERVIEW OF MEGen
MEGen is a code generator that eliminates the need to formulate
and code a set of equations. It consists of two components: a PBPK
parameter database and amodel EG.Both components canbeused
as stand-alone applications although the EG is conﬁgured to inter-
rogate the database during the model building process. The user is
engaged in a dialog relating to the details of the physiology of the
system to be modeled and the biochemistry and physicochemistry
of the compound of interest. On the basis of this information,
a script is produced in XML. The XML can be transformed into
5www.datatrendsoftware.com
alternative markup (e.g., MathML) or plain text for use in model-
ing software packages such as acslX,MATLAB,BerkeleyMadonna,
andMCSim. This greatly reduces development time (from several
hours to minutes) and removes the need for any mathematical
expertise. In addition, a schematic of the model and a report in
the form of a table of model parameters listing the source refer-
ence can be exported for use in most standard word processors. A
summary of the components and outputs of MEGen is shown in
Figure 1.
THE PBPK DATABASE
The anatomical, physiological, biochemical, and physicochemi-
cal data required to build PBPK models reside in a speciﬁcally
designed electronic database. The data currently stored in the
database are predominantly from the peer-reviewed literature
describing speciﬁc PBPK models (Pastino et al., 2000; Clewell
et al., 2001; Himmelstein et al., 2004; Sultatos et al., 2004) and
a summary of PBPK model parameters reported by Brown et al.
(1997) Different values for parameters are stored along with their
source making selection for a model easy, rapid, and transparent.
The database can be used in isolation or as part of model build-
ing in the EG. Figure 2 is a screenshot of the browse page. In
this example, a rat muscle tissue: air partition coefﬁcient for vinyl
chloride is selected. Various types of information regarding this
datum are displayed, e.g., a mean value, standard error, sample
number, and method used to derive the datum. If less informa-
tion were available from the source reference, such as, the datum is
reported as a point value only then those various ﬁelds can be left
empty. The source reference is displayed along with an indication
as to whether the datum is original or not. A datum is consid-
ered original if the information was determined experimentally
and reported for the ﬁrst time. There is an optional “Comments”
ﬁeld, which could be used to add further information such as,
page or table number indicating where the datum may be found
in the source document. Information regarding the user and date
of datum entry can be entered in the “Ref” ﬁeld. A datum may be
FIGURE 1 | MEGen components and outputs.
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FIGURE 2 | Database search page showing details of a selected parameter.
edited, deleted, or cloned by clicking the pen, delete, or clone sym-
bols at the bottom of the datum information box. The fourth icon
allows selection of data that may be assembled and managed as
a batch. The browse page also contains hyperlinks to other pages
that allow new data entry, such as new species of experimental
animal, new chemical and new reference from which data were
retrieved.
The database includes a powerful search engine and a compre-
hensive querying syntax. Search terms are separated with oper-
ators (and, or, ∼, ∗, –) and grouped using (parentheses). Filter
expressions are enclosed in [square brackets]. Examples of the
MEGen search syntax are given in Table 1 and displayed as user
information in the browse page by hovering the cursor over the
information button to the right hand side of the search ﬁeld
(Figure 2). A search ﬁlter may also be conﬁgured by selecting
animal, chemical, and source by hovering the cursor over the gear
wheel symbol on the right hand side of the information button
(Figure 3).
THE EQUATION GENERATOR
A schematic of the simplest, viable PBPK model is displayed on
the initial conﬁguration page of the EG (Figure 4). The sim-
plest model comprises two aggregated compartments, the slowly
Table 1 | MEGen: PBPK database search terms.
Search terms Returns
Dog or rat Returns data with a ﬁeld that contains either of
these words
Human and intestine Returns data with ﬁelds containing both these
words
Tissue∼blood Returns data where these terms occur in close
proximity
Chlor* Finds chlorobenzene, chlorine, beta-chloroprene,
etc.
(Rat or mouse) and heart Returns heart data for rats or mice
[Animal= rat] V max Finds V max values speciﬁcally for rats
Rat [strain∼ﬁscher* or
sprague*] liver
Finds data containing any mention of rat or liver,
but speciﬁcally where the strain startswith either
Fischer or Sprague
and rapidly perfused tissues. The slowly perfused compartment
contains adipose, bone, muscle, and skin. The rapidly perfused
compartment contains the adrenal, brain, gut, heart, kidney, large
intestine, liver, lung, ovaries, pancreas, small intestine, spleen,
stomach, testes, thymus, and thyroid. As organs and tissues are
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FIGURE 3 | Database search page: application of filters.
selected and deﬁned discretely their associated masses and blood
perfusion rates are subtracted from the aggregated compartments
thereby conservingmass-balance. A keyword summary of the four
main categories of data, i.e., animal, chemical, exposure routes, and
organs and tissues is listed below the schematic and updated dur-
ing parameter selection. Model labels, subject species, chemical,
exposure routes (selection of exposure routes page not shown),
and compartments are selected by clicking the appropriate tabs
(Figures 5A–C). The equations used in MEGen for inhalation,
intra-venous, oral, and dermal exposure are described by Krish-
nan and Andersen (1994) and for closed-chamber simulation by
Gargas et al. (1986). The context of each compartment is dis-
played, i.e., slowly or rapidly perfused. Metabolic elimination may
be enabled in any selected organ or tissue. The schematic is con-
tinually updated during organ and tissue selection (not shown
here due to space restrictions). Figure 6 is an example of a com-
plete schematic for inhalation exposure of the rat to vinyl chloride,
with adipose, lung, stomach, and liver compartments selected,
and metabolic elimination enabled only in the liver. Note the
updated keyword summary of the model displayed at the bot-
tom of the schematic. It is noteworthy that when using MEGen
the lung is conﬁgured to receive the bronchial blood supply,
with the pulmonary blood supply only taking part in gaseous
exchange. Various options such as, calculation of organ volume
from fractional mass and organ density, diffusion limited uptake,
the calculation of tissue blood partition coefﬁcients from tissue:
air partition coefﬁcients, and in vitro to in vivo extrapolation of
Vmax are available in the “Modes” page.
Model parameters are selected by clicking “Continue” in the
conﬁguration data scheme page to enter the “Populate Model”
page.Model parametersmaybe selectedusing the“PopulateCaddy
or Review Data Scheme” options. Figure 7 is a screenshot of the
“Add to Caddy” page accessed by clicking the “Populate Caddy”
option. Parameters are selected by clicking on an abbreviation
for a parameter. The database is interrogated and returns either a
single or a selection of relevant parameters (this depends on the
ﬁlters applied). If a datum is present a green tick appears next to
“present” and the details, including the source are displayed in the
space below. In this example the body mass (BW) of the rat was
found. The parameter may be added to the caddy by clicking on
the “Add” button on the right hand side. Parameters with a super-
script ∗ are obligatory model inputs and those with superscript †
offer a choice to the user. Examples of the latter type of parameter
are cardiac output (QC∗) and respiration rate (QP∗) where the
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FIGURE 4 | Initial configuration page.
FIGURE 5 | Configuration pages: selection of, (A) animal, (B) chemical, and (C) compartments.
value may be calculated using an allometric equation or a user
deﬁned value applied directly within the model. If a datum were
not present a value for the parameter would need to be entered
manually later in the “Review Data Scheme” page.
The PBPK model may be automatically populated by click-
ing “Conﬁgure/Autopopulate” to enter the “Caddy Editor” page
(Figure 8). The Caddy Editor offers another opportunity to select
or remove parameters. Checking the box at the top left selects all
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FIGURE 6 | Configuration page: selection of optional parts of model.
FIGURE 7 | Parameter selection using the Caddy.
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FIGURE 8 | Auto-population of model using the Caddy editor.
FIGURE 9 | Model review page.
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FIGURE 10 | Generate code page.
parameters, which is indicated by the presence of a tick next to
each parameter. The model is automatically populated by select-
ing “Empty or New” from the drop down menu at the top right
hand side and clicking on“Save andAutopopulate.”Conﬁrmation
that the parameter(s) have been added to the model occurs when
the words “Not used,” which appear next to the instruction drop
downmenu box, are replacedwith“Added.”Themodel is reviewed
by clicking on “Review” to enter the “Review Data Scheme” page
where parameters may be altered or added (Figure 9). Parameters
such as, simulation run time, exposure concentration or dose and
exposure on/off switches may be conﬁgured here. The green tick
indicates that the datum is correctly conﬁgured; the green ques-
tion mark indicates that a datum has been edited and requires to
be uploaded; the red question mark indicates that a mandatory
datum is missing and must be added for correct conﬁguration.
Various speciﬁc options are available in the Review Data scheme
page, e.g., a closed-chamber exposure experiment could be simu-
lated by clicking on the“Concept – Single Compound”node to add
“closed-chamber experiment” (not shown, although in this ﬁgure
this option was selected and the parameters required for this type
of simulation appear within the node). However, another example
of the selection of a speciﬁc option is shown in Figure 9 where oral
uptake, glutathione conjugation and dose metrics can be added to
a model by clicking on the “Compound” node to reveal a pop-up
menu. Similarly, more metabolic eliminations may be added to a
compartment in which metabolism is already enabled by clicking
on the appropriate compartment node. The liver compartment
is not visible in Figure 9 but clicking on the liver compartment
node would reveal a pop-up menu allowing the addition of extra
metabolism.
When all parameters have a green tick the model may be
uploaded, translated and rendered into MathML by clicking
on “Script.” The MathML script is displayed on the “Gener-
ate Code” page (Figure 10). Code may be saved in a choice
of native syntax formats, which can be exported and run in
several simulation packages where it may be visualized and
exercised. A report containing a conceptual view of the data
schema, showing the hierarchical arrangement of parameter
groupings and a table of parameters, may also be downloaded
from this page. An example of a conceptual view of the data
schema is shown in Figure 11. This could serve as a concise
summary of the model. The hierarchical representation of the
model permits information to be contained in a nested way.
The reviewer can immediately see the entire model which is
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FIGURE 11 | A conceptual view of the data schema showing the
hierarchical arrangement of parameter groupings.
enclosed by the beginning and ending “elements,”<Model> and
</Model>, respectively. The rootmodel information is contained
within this element. All exposure routes are contained within
the beginning and ending exposure elements, <Exposure> and
</Exposure>. All compartments are contained within the begin-
ning and ending compartment elements,<Compartments> and
</Compartments>. Compartment speciﬁc information such as
partition coefﬁcients, fractional blood ﬂow and mass, and meta-
bolic rate constants are contained within the beginning and
ending elements of a speciﬁc compartment, e.g., <Liver> and
</Liver>.
CHECK FUNCTIONS
Generated code is designed to be robust to modiﬁcation outside
of MEGen due to the presence of a number of check functions.
The conﬁguration of the bronchial blood supply to the lung
parenchyma is one example of a check function. Another is the
subtraction of organ masses and blood perfusion rates from the
aggregated compartments to conserve mass-balance. An impor-
tant and useful feature of MEGen code is an expression to ensure
that mass-balance is preserved. Manual alterations to code can
create inconsistencies in the equations, leading to predictions that
do not correspond to the modeling assumptions. By inserting
a check function that calculates the quotient of mass delivered
and amount present in the compartments as well as the amount
excreted, it is possible to plot this function over time. A similar
check is often provided in PBPK models; plotting mass delivered
against mass present/excreted in all compartments. Figure 12A
(left hand panel) is an illustration of the plot of the quotient of
mass over dose for a model in which there is a small linear error
in a compartment (e.g., such errors can occur if source and sink6
terms between parent compound and metabolite are not properly
matched).Whilst Figure 12B (right hand panel) is the plot of mass
versus dose which appears to show a preservation of mass-balance,
the plot of the quotient of mass and dose clearly shows a relative
error that is exponentially increasing with time. The plot of mass
versus dose approach is not as effective in that small errors that
could become signiﬁcant under different exposure patterns can
go unnoticed. The beneﬁt of the quotient approach is that even
tiny deviations from the expected value of 1 are clearly visible on a
plot with a narrow vertical y-range, and since the function is plot-
ted against time, the user can see the time points at which errors
occur/propagate.
The mass-balance check function should be used after every
manual alteration made to the model code. Building such check
functions into code generated using MEGen increases the chances
of trapping errors in the code that may subsequently be manually
adjusted. In acslX syntax this function is expressed as:
rel = mass/(dose + 1e-10)
The 1e-10 statement prevents division by zero when dose= 0.
In practice, this is only likely to occur before exposure (usually at
time= 0). The disadvantage of this approach is that mass/balance
errors that occur when dose= 0 will not be highlighted. However,
given that dose is amonotonically7 increasing function, this should
never occur. Figure 12C shows the mass-balance check function
for the vinyl chloride model (discussed below) visualized in acslX
Libero. Mass-balance is conserved over the entire simulation, as
there is no deviation from 1.
SAMPLE OUTPUTS
MEGen was evaluated by reproducing three PBPK models from
the peer-reviewed literature. The anatomical, physiological, bio-
chemical, and physicochemical parameters for all three PBPK
models were entered into the database and are reproduced here
in Tables 2–4.
β-CHLOROPRENE
In the ﬁrst example, closed-chamber gas uptake studies for the
inhalation exposure of the B6C3F1 mouse to β-chloroprene were
simulated by building the PBPK model developed by Himmel-
stein et al. (2004). The model built using MEGen differed in that
it included the bronchial blood supply to the lung parenchyma.
As described previously this is a default conﬁguration in MEGen.
6A “source” term creates compound within the model. A “sink” term removes
compound within from the model.
7Changing in one direction only; thus either always rising or always falling, but not
reversing direction.
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FIGURE 12 | Mass-balance check functions: quotient, dose against mass, and mass/dose quotient against time plot for the vinyl chloride model
exported and visualized in acslX Libero.
Gaseous exchange occurs with the pulmonary blood supply. How-
ever, the sensitivity of the bronchial blood supply and metabolic
capacity ascribed to the lunghad anegligible effect on theuptake of
β-chloroprene from the closed-chamber atmosphere (Figure 13).
The model was built and exported in Berkeley Madonna syntax
and run to reproduce Panel A in Figure 2 from Himmelstein et al.
(2004).Model construction, simulation and graphical outputwere
completed in about 10min. Exact ﬁt through the datawas achieved
with minor iterative changes to mouse BW or ventilation rate.
VINYL CHLORIDE
The PBPK model for vinyl chloride (VC) developed by Clewell
et al. (2001), which included the depletion of glutathione by the
metabolic products of VC was built. The mass-balance equations
for glutathione conjugation with oxidized metabolites are identi-
cal to those reported byD’Souza et al. (1988). Rats were exposed by
inhalation for 4 h to a constant concentration of VC. Although the
original work referred to the use of Sprague-Dawley, Wistar, and
Fisher-344 rats there is, in fact, little to distinguish between these
strains except on BW. Therefore, the parameters used in MEGen
are for a “generic” rat. The model was built and exported in acslX
syntax and run in that platform to reproduceFigure 5 fromClewell
et al. (2001) showing the dose-dependent depletion of glutathione
(Figure 14). Model construction, simulation, and graphical out-
put were completed in about 10min. The glutathione conjugation
option in the current version of MEGen demonstrates a proof-of-
principle: that future development can include other important
modes-of-action.
ETHANOL
The human PBPK model containing genetic polymorphisms in
ethanol metabolism described by Pastino et al. (2000) was sim-
pliﬁed by excluding the brain and comprised the adipose, liver,
and slowly and rapidly perfused compartments. Metabolism was
enabled in the liver and included three isoenzymes of alco-
hol dehydrogenase in addition to cytochrome P450. Exposure
was by the intra-venous route and the output was compared to
mean experimental blood ethanol concentrations from six adult
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Table 2 | Anatomical and physiological parameters used for the three
PBPK models.
Physiological
parameters
Mouse β-
chloroprene
model
Rat vinyl
chloride
model
Human
ethanol
model
Vascularized tissuea
(proportion of BW)
0.893 0.927 0.857
VALUES FOR SIMULATION OF CLOSED-CHAMBER GAS UPTAKE
DATA OR CONSTANT INHALATION EXPOSURE
Chamber volume (L) 3.8
Body weight (kg) 0.024–0.034 0.342 n/a
Ventilation (L/h/kg) 15 21 n/a
Cardiac output (L/H/kg) 15 18 n/a
TISSUEVOLUMESAS FRACTION OF BODYWEIGHT
Liver 0.055 0.04 0.026
Fat 0.05 0.07 0.214
Rapidly perfusedb 0.077
Slowly perfused 0.77 0.75 0.561
Lung 0.0073 0.0076
BLOOD FLOWAS FRACTION OF CARDIAC OUTPUT
Liver 0.161 0.25 0.227
Fat 0.07 0.09 0.052
Rapidly perfused 0.51 0.472
Slowly perfused 0.15 0.15 0.249
Lung 0.005c –
aCalculated by subtracting bone mass from total tissue mass [from Table 21 in
Brown et al. (1997)].
bCalculated by MEGen.
cBrown et al. (1997).
Table 3 |Tissue-to-air partition and tissue-to-blood coefficients used in
the three PBPK models.
Tissue Mouse Rata Humanb
Blood 7.8 2.4 1265
Lung 18.6 – –
Liver 9.8 0.7 0.81
Fat 135.3 10 0.11
Muscle 4.6 – –
Kidney 13.7 – –
Rapidly perfused 0.7 0.95
Slowly perfused 0.4 0.8
aTissue: blood partition coefﬁcients (Clewell et al., 2001).
bTissue: blood partition coefﬁcients (Pastino et al., 2000).
subjects infused with 0.4 g kg−1 for 1 h (error bars not displayed;
Figure 15). The model was built and exported in MATLAB syn-
tax and run on that platform to reproduce Figure 5 from Loizou
and Spendiff (2004; experience with MATLAB is recommended
in order to run and plot the generated function model). Model
construction, simulation, and graphical output were completed in
about 10min.
Table 4 | Metabolic parameters used in the three PBPK models.
Biochemical
parameters
Mouse (β
chloroprene)
Rat (vinyl
chloride)
Human
(ethanol)
Units
METABOLIC RATE CONSTANTS
V max liver HA 39.2 4a mg/h/
kg/bw
KM liver HA 0.091 0.1a mg/L
V max lung HA 1.02 mg/h/
kg/bw
KM lung HA 0.13 mg/L
V max liver LA 2b mg/h/
kg/bw
KM liver LA 10b mg/L
V max
liverP4502E1
36 mg/h/kg/bw
KM liverP4502E1 575 mg/L
V max liver ADHαα 54 mg/h/kg/bw
KM liver ADHαα 193.5 mg/L
V max liver ADHβ1 17.5 mg/h/kg/bw
KM liver ADHβ1 2.3 mg/L
V max liver
ADH2c2
35 mg/h/kg/bw
KM liver ADH2c2 29 mg/L
GLUTATHIONE METABOLISM
KGSMCc 0.13 μmol/h
KFEECd 35 /h
KOCe 28.5 μmol/h
KBCf 0.12 /h
KSg 2000 μmol/h
GS0h 5800 μmol/h
aHA, high afﬁnity metabolism.
bLA, low afﬁnity metabolism.
cGSH conjugation rate constant with metabolite.
dnon-GSH conjugation rate with metabolite.
eZero-order GSH production rate.
fFirst-order GSH breakdown rate.
gResynthesis constant.
hInitial GSH concentration.
DISCUSSION
The current version of MEGen is able to quickly generate and ana-
lyze standard parent chemical-only PBPK models. It provides full
model transparency and reproducibility, shifts the emphasis away
from the need for considerable mathematical and programming
skills to the biology of RA, saves time and money, and has massive
scope for further development. The routes of exposure currently
available are simple descriptions of these processes, but like any of
the features described in MEGen,more sophisticated descriptions
can be added if required.
Several features available in MEGen are consistent with the
recommendations of recent international initiatives on global har-
monization of RA. The International Program on Chemical Safety
(IPCS) steering group of the World Health Organization (WHO)
identiﬁedPBPKmodeling as an important component of chemical
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FIGURE 13 | Reproduction of Figure 2A from Himmelstein et al. (2004). In vivo closed-chamber gas uptake of β-chloroprene in the B6C3F1 mouse. Mean
experimental data (symbols) and simulations (lines) represent initial concentrations of 2, 10, 50 270, or 363 ppm. PBPK model exported in Berkeley Madonna
syntax.
FIGURE 14 | Reproduction of Figure 5 from Clewell et al. (2001). Simulations (lines) and experimentally determined (symbols) glutathione concentrations (as
percent of control animal levels) at 0, 20, and 44 h following 4-h inhalation exposures to VC at •5760, 192, 57.6, 19.2, and ×5.76 ppm. PBPK model
exported in acslX Libero version 3.0.1.6.
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FIGURE 15 | Reproduction of Figure 5 from Loizou and Spendiff (2004). Simulated (line) versus measured (symbols) blood ethanol concentrations following
intra-venous administration of 0.4 g kg−1 ethanol for 1 h. PBPK model exported in MATLAB version R2010b.
RA that merits international harmonization8. A notable action
of this group was to convene an International Workshop on the
Development of Good Modeling Practice (GMP) for PBPK mod-
els (Loizou et al., 2008). An important recommendation of the
workshop was that the development of guidelines for GMP is best
achieved through a cross-disciplinary exchange of experience and
ideas among laboratory scientists, PBPKmodelers, regulators, and
risk assessors. The development of GMP is therefore predicated on
good communication between scientists involved in the different
stages of chemical RA. We propose that MEGen is an ideal tool
that can help facilitate such cross-disciplinary communication.
Indeed, related to this was another recommendation made at the
same workshop that MEGen (earlier version) should be adapted
as a potentially useful teaching tool that could be used to demon-
strate to undergraduate and graduate students how quantitative
biological knowledge can be applied to solve real-world problems
(Loizou et al., 2008).
MEGen is a labor saving device that permits the rapid construc-
tion of PBPK models. There are a number of potential beneﬁts
related to this. PBPK models submitted as part of chemical RA
could be reproduced and evaluated by regulatory agencies. Simi-
larly, thorough peer-review of a PBPKmodel can only be achieved
8http://www.who.int/ipcs/methods/harmonization/areas/pbpk/en/index.html
if the model is reproduced. It is conceivable that specialist jour-
nals in the future would require models be reproduced during the
peer-reviewed process.
Finally, further development will broaden the applicability of
MEGen. For example, as models become increasingly sophis-
ticated the library of governing equations will be continually
extended to include, enhanced oral uptake, micturition, a wash-
in/wash-out inhalation route, and other functional forms. The
option to populate a model using in silico-derived parameters
will be made available using an in-built quantitative structure
activity relationship (QSAR) algorithm for the prediction of
partition coefﬁcients and state of the art in vitro to in vivo
scaling for the use of experimentally derived metabolic rate
constants. The preparation of PBPK model code for stochastic
analysis such as population-based modeling using Monte Carlo
and Markov Chain Monte Carlo sampling and global sensitiv-
ity analysis will also be available. Importantly, a template that
provides a standard document with model information that has
been established as pertinent to regulators will be an optional
output.
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